

MYCN Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP7395b**Specification**

MYCN Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [P04198](#)**MYCN Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 4613**Other Names**

N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37, MYCN, BHLHE37, NMYC

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7395b](/products/AP7395b) was selected from the C-term region of human MYCN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MYCN Antibody (C-term) Blocking Peptide - Protein Information**Name** MYCN**Synonyms** BHLHE37, NMYC**Function**

Positively regulates the transcription of MYCNOS in neuroblastoma cells.

Cellular Location

Nucleus.

Tissue Location

Expressed in the neuronal cells of the cerebrum, neuroblastomas and thyroid tumors (at protein level)

MYCN Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

MYCN Antibody (C-term) Blocking Peptide - Images

MYCN Antibody (C-term) Blocking Peptide - Background

MYCN is a member of the MYC family and a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of its gene is associated with a variety of tumors, most notably neuroblastomas.

MYCN Antibody (C-term) Blocking Peptide - References

Combaret,V., *Pediatr Blood Cancer* 53 (3), 329-331 (2009) Alvarez-Rodriguez,R., *J. Cell. Sci.* 122 (PT 5), 595-599 (2009) Jacobs,J.F., *BMC Cancer* 9, 239 (2009)